News

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor

ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that S&P Global Ratings (S&P) upgraded ICON to an investment grade credit rating

Novocure (NASDAQ: NVCR) today announced it has entered into an agreement with Stanford University to establish the Stanford School of Medicine Tumor Treating Fields (TTFields) Research Program. The

QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI^® (encorafenib) + MEKTOVI^® (binimetinib) for the treatment of adult patients with

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI^® (encorafenib) + MEKTOVI^® (binimetinib) for the treatment of adult patients with

Regulatory News:

POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report fourth quarter and fiscal 2023 financial results after the market close on Wednesday, October 25

Premier, Inc. (NASDAQ: PINC) today announced that it will release financial results for its fiscal 2024 first quarter on Tuesday, November 7, 2023, at approximately 6:30 a.m. ET. The company will

Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report third quarter 2023 financial

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported preliminary financial and operational highlights for

Regulatory News:

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, and BioInvent International AB (“BioInvent”) (Nasdaq

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to three new employees.

On October 3

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced its Board of Directors has appointed J. Christopher Barry to the Board, effective today. Barry will serve on the

Pfizer Inc. (NYSE: PFE) will present data across its infectious disease portfolio at the upcoming IDWeek 2023 held in Boston from October 11-15, 2023. Data from 45 abstracts will highlight the

Pfizer Inc. (NYSE: PFE) will present data across its infectious disease portfolio at the upcoming IDWeek 2023 held in Boston from October 11-15, 2023. Data from 45 abstracts will highlight the

Humana, a leading health and well-being company, and Denver Health, a comprehensive health and hospital system, have entered into an agreement that broadens access to care for Humana Medicare

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on October 2, 2023, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.41 fourth-quarter 2023 dividend on the company’s common stock, payable December 4, 2023, to holders of the Common